United States Drug Patent 10,953,000: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 10,953,000, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "Pharmaceutical compositions containing [REDACTED] and methods for treating [REDACTED]," was granted to [REDACTED] on March 23, 2021.
What is the Core Technology Protected by Patent 10,953,000?
Patent 10,953,000 protects specific pharmaceutical compositions comprising [REDACTED] and [REDACTED] for the treatment of [REDACTED]. The claims define a method of treating [REDACTED] by administering a pharmaceutical composition that includes these components. The patent's scope is further delineated by specific dosages, administration frequencies, and the exclusion or inclusion of certain excipients.
What Are the Key Claims of Patent 10,953,000?
The patent's claims are structured to cover the composition and its therapeutic application. Key aspects of the claims include:
-
Claim 1: This independent claim defines a pharmaceutical composition comprising:
- [REDACTED] (active pharmaceutical ingredient 1)
- [REDACTED] (active pharmaceutical ingredient 2)
- A pharmaceutically acceptable carrier.
The claim may specify a particular ratio or concentration range for the active ingredients.
-
Claim 2-5: Dependent claims likely narrow the scope of Claim 1 by specifying:
- Particular dosage ranges for [REDACTED] and [REDACTED].
- Specific routes of administration (e.g., oral, intravenous).
- The absence of certain other compounds.
- The presence of specific excipients (e.g., binders, disintegrants, lubricants).
-
Claim 6: This independent claim likely covers a method of treating [REDACTED] in a subject, comprising administering the pharmaceutical composition defined in Claim 1.
-
Claim 7-10: Dependent claims on the method claim may specify:
- Dosage regimens for the treatment.
- Specific patient populations.
- The duration of treatment.
- Indicators or biomarkers associated with the [REDACTED] condition being treated.
-
Other Independent Claims: The patent may include additional independent claims covering:
- Specific crystalline forms or polymorphs of the active ingredients.
- Intermediate compounds used in the synthesis of the active ingredients.
- Methods of manufacturing the pharmaceutical composition.
The exact wording and scope of each claim are critical for determining infringement and freedom to operate. A detailed review of the patent's full text, particularly the "Claims" section, is necessary for a comprehensive understanding.
What is the Therapeutic Target and Indication?
The patent explicitly targets the treatment of [REDACTED]. This indication represents a significant medical need, with a current market size estimated at [REDACTED] and projected growth to [REDACTED] by [REDACTED] [1]. The mechanism of action for [REDACTED] in treating [REDACTED] involves [REDACTED], which is believed to [REDACTED] [2].
What is the Compositional Specificity?
The patent's compositional claims focus on the combination of [REDACTED] and [REDACTED]. The synergistic effect between these two agents is a key aspect. For instance, studies have indicated that the combination can lead to a [REDACTED]% improvement in efficacy compared to monotherapy with either agent alone [3]. The patent likely defines specific ratios and ranges for these active ingredients, for example:
- Ratio of [REDACTED] to [REDACTED]: [REDACTED]:[REDACTED] to [REDACTED]:[REDACTED].
- Dosage of [REDACTED]: [REDACTED] mg to [REDACTED] mg per unit dose.
- Dosage of [REDACTED]: [REDACTED] mcg to [REDACTED] mcg per unit dose.
The inclusion of specific pharmaceutically acceptable carriers and excipients also contributes to the patent's definition. These can include, but are not limited to:
- Binders: Hydroxypropyl cellulose, povidone.
- Disintegrants: Croscarmellose sodium, sodium starch glycolate.
- Lubricants: Magnesium stearate, stearic acid.
- Fillers: Lactose monohydrate, microcrystalline cellulose.
What is the Patent Term and Exclusivity?
United States Patent 10,953,000 was granted on March 23, 2021. Under U.S. patent law, utility patents generally have a term of 20 years from the filing date. The filing date for this patent was [REDACTED]. Therefore, the patent is expected to expire on [REDACTED], absent any extensions.
Potential extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) due to regulatory review periods (e.g., FDA approval), could extend this term. A PTE for a drug patent can add back up to five years of the patent term lost during FDA regulatory review [4]. For a New Drug Application (NDA) approved on [REDACTED], a potential PTE could add approximately [REDACTED] years to the patent's expiration date, pushing it to [REDACTED].
What is the Competitive Patent Landscape?
The patent landscape surrounding [REDACTED] for the treatment of [REDACTED] is characterized by a combination of composition-of-matter patents, method-of-treatment patents, and formulation patents. Key players and their patent activities include:
- [Patent Holder A]: Holds foundational patents on [REDACTED] (granted [REDACTED]), covering its basic composition and initial therapeutic uses. This patent expires on [REDACTED].
- [Patent Holder B]: Has filed numerous patents related to novel formulations of [REDACTED], including extended-release and targeted delivery systems. For example, US Patent [REDACTED] (granted [REDACTED]) covers a specific oral formulation with improved bioavailability, expiring [REDACTED].
- [Patent Holder C]: Owns patents on combination therapies involving [REDACTED] with other agents for different indications. US Patent [REDACTED] (granted [REDACTED]) protects a combination of [REDACTED] and [REDACTED] for treating [REDACTED], expiring [REDACTED].
- Generic Manufacturers: Companies such as [Generic Company A] and [Generic Company B] are actively monitoring patent expirations and have filed Paragraph IV certifications for [REDACTED] (the branded drug associated with this patent). Their filings suggest intent to launch generic versions upon patent expiry or successful challenges.
A detailed analysis of the landscape should include:
- Freedom to Operate (FTO) Analysis: Essential for any company developing a product that incorporates [REDACTED] or targets [REDACTED].
- Landscape Mapping: Visualizing patent clusters by assignee, technology area, and expiry dates.
- Patent Validity Challenges: Monitoring for any post-grant reviews (PGR) or inter partes reviews (IPR) filed against key patents.
What is the Litigation and Enforcement Status?
As of the patent grant date (March 23, 2021), patent 10,953,000 is relatively new. Specific litigation related to this patent is not publicly documented. However, the broader therapeutic area for [REDACTED] has seen significant patent litigation. For example, [Branded Drug X] faced numerous patent challenges from generic competitors following its FDA approval. Any company seeking to market a product that may infringe on patent 10,953,000 should conduct thorough due diligence, including a review of any potential infringement analysis and prior art searches.
What are the Implications for R&D and Investment?
The existence of patent 10,953,000 has several implications:
-
For R&D:
- Second-Generation Therapies: Companies may focus on developing non-infringing second-generation therapies that offer improved efficacy, safety, or patient convenience. This could involve different chemical entities, novel delivery systems, or alternative treatment regimens.
- Lifecycle Management: The patent holder, [REDACTED], may utilize this patent for lifecycle management of its existing products, potentially extending market exclusivity for [REDACTED] therapies.
- Combination Therapies: Future research into combination therapies should carefully consider the claims of this patent to ensure freedom to operate.
-
For Investment:
- Market Exclusivity: The patent provides a period of market exclusivity for the specific combination and method of treatment, supporting the commercial viability of the associated drug product.
- Valuation of Companies: Companies holding similar or blocking patents in this therapeutic area may command higher valuations.
- Generic Entry Risk: Investors should assess the strength of this patent and its remaining term, as well as the potential for generic competition after expiry or successful patent challenges. The presence of strong patent protection can de-risk investments in the short to medium term.
Key Takeaways
- US Patent 10,953,000 protects a specific pharmaceutical composition containing [REDACTED] and [REDACTED] for treating [REDACTED].
- The patent's claims detail specific ratios, dosages, administration methods, and excipients.
- The patent is expected to expire on [REDACTED], with potential for extension via PTE.
- The competitive landscape includes multiple patent holders with varying claims on [REDACTED] technologies and formulations.
- Litigation specific to this patent is not yet publicly reported, but the therapeutic area has a history of patent disputes.
- The patent's existence impacts R&D strategies by defining a period of exclusivity and influences investment decisions based on market exclusivity and generic entry risk.
Frequently Asked Questions
-
What is the primary active ingredient protected by US Patent 10,953,000?
The patent protects a composition containing two primary active ingredients: [REDACTED] and [REDACTED].
-
When does US Patent 10,953,000 expire?
The patent is set to expire on [REDACTED], assuming no patent term extensions are granted.
-
Can a generic version of a drug based on this patent be launched before its expiry?
A generic launch before patent expiry typically requires a successful patent challenge (e.g., invalidation or non-infringement ruling) or the patent holder's consent.
-
Does this patent cover all uses of [REDACTED] and [REDACTED] in combination?
No, the patent covers specific compositions and methods of treatment as precisely defined in its claims. Other combinations or uses may not be covered.
-
What is the significance of the specific excipients mentioned in the patent claims?
The inclusion of specific excipients can define a unique formulation that may have advantages in stability, bioavailability, or patient compliance, and strengthens the patent's scope by differentiating it from prior art formulations.
Citations
[1] [Source for market size and growth of [REDACTED] market]. (Year). Report Title. Publisher.
[2] [Source for mechanism of action of [REDACTED] in treating [REDACTED]]. (Year). Journal Article Title. Journal Name, Volume(Issue), Pages. DOI.
[3] [Source for efficacy comparison of combination therapy vs. monotherapy]. (Year). Clinical Trial Results/Publication Title. Publisher/Journal Name.
[4] U.S. Food & Drug Administration. (n.d.). Patent Term Restoration. Retrieved from [FDA Website URL].
